Evidence map›Paper›PMID 30065560›Full record

ArticleWorld journal of gastroenterology2018

Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas.

Yan-Zhou Song, Xu Li, Wei Li, Zhong Wang, Kai Li, Fang-Liang Xie, Feng Zhang

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan-Zhou SongDepartment of General Surgery, Lianyungang Clinical Medical College of Nanjing Medical University/The First People's Hospital of Lianyungang, Lianyungang 222002, Jiangsu Province, China.
Xu LiDepartment of Liver Surgery/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Wei LiDepartment of General Surgery, The First People's Hospital of Lianyungang, Lianyungang 222002, Jiangsu Province, China.
Zhong WangDepartment of General Surgery, The First People's Hospital of Lianyungang, Lianyungang 222002, Jiangsu Province, China.
Kai LiDepartment of General Surgery, The First People's Hospital of Lianyungang, Lianyungang 222002, Jiangsu Province, China.
Fang-Liang XieDepartment of General Surgery, The First People's Hospital of Lianyungang, Lianyungang 222002, Jiangsu Province, China.
Feng ZhangDepartment of Liver Surgery/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the prognostic power of different molecular data in liver cancer.

methodsCox regression screen and least absolute shrinkage and selection operator were performed to select significant prognostic variables. Then the concordance index was calculated to evaluate the prognostic power. For the combination data, based on the clinical cox model, molecular features that better fit the model were combined to calculate the concordance index. Prognostic models were built based on the arithmetic summation of the significant variables. Kaplan-Meier survival curve and log-rank test were performed to compare the survival difference. Then a heatmap was constructed and gene set enrichment analysis was performed for pathway analysis.

resultsThe mRNA data were the most informative prognostic variables in all kinds of omics data in liver cancer, with the highest concordance index (C-index) of 0.61. For the copy number variation, methylation and miRNA data, the combination of molecular data with clinical data could significantly boost the prediction accuracy of the molecular data alone (

conclusionIn all kinds of omics data in liver cancer, the mRNA data might be the most informative prognostic variable. The combination of clinical data with molecular data might be the future direction for cancer prognosis and prediction.

Indexed as

Models, BiologicalBiomarkers, TumorDatabases, GeneticDNA Copy Number VariationsDNA MethylationFemaleGene Expression ProfilingGenomicsHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedPredictive Value of TestsPrognosisProportional Hazards ModelsBiomarkers, TumorMicroRNAsRNA, MessengerC-indexEvaluationLiver cancerMolecular markerPrognosis

Identifiers

PMID30065560
PMCPMC6064958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.